Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Niacin + laropiprant + simvastatin
- Development stage
- Discontinued
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Niacin + laropiprant + simvastatin is a fixed-dose combination drug developed for the treatment of primary hypercholesterolemia or mixed dyslipidemia. It combines three agents: extended-release niacin (a lipid-modifying agent that raises HDL cholesterol and lowers LDL cholesterol and triglycerides), laropiprant (a selective prostaglandin D2 receptor [DP1] antagonist used to reduce flushing caused by niacin), and simvastatin (an HMG-CoA reductase inhibitor, or statin, that lowers LDL cholesterol). The rationale for this combination is to provide comprehensive lipid management while improving tolerability of niacin therapy. The product was developed by Merck Sharp & Dohme Corp., but clinical development was discontinued before regulatory approval[2][4][5][8].
- Other names
- ERN/LRPT/SIMextended-release niacin/laropiprant/simvastatin
02
Targets
HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PTGDR (Prostanoid DP1 receptor)HCAR2 (Hydroxycarboxylic acid receptor 2)
Beyond the preview
Go deeper on Niacin + laropiprant + simvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Niacin + laropiprant + simvastatin.